Dialysis world news


Korle-Bu to begin Kidney transplant in last quater - GhanaWeb

General News of Monday, 14 May 2012

Source:Daily Graphic

Kidney Transplant

Doctors at the Korle-Bu Teaching Hospital (KBTH) will begin undertaking kidney transplantation in the last quarter of this year.

This will bring great relief to many kidney patients in the country who need kidney transplant but cannot afford the high cost of travelling and transplantation abroad.

Since 2008, the nation’s premier hospital has undertaken 12 kidney transplants with the assistance of a team of transplant surgeons from Birmingham in the United Kingdom and the Transplant Links Community.

Three of those transplants were performed in April this year.

The Birmingham team is expected to perform another batch of transplants in October this year, after which the Ghanaian team will take over.

Meanwhile, Korle-Bu has sponsored the training of a consultant urologist, Dr Bernard Morton, as a transplant surgeon to lead a local team to bring hope to many kidney patients.

Currently, the Dialysis Unit at Korle-Bu, which used to operate three times a week, now runs 24-hour, seven-day-a-week service because of the increasing number of chronic patients.

An excited Chief Executive Officer of the hospital, Professor Nii Otu Nartey, in an interview with graphic.com.gh, said Korle-Bu would endeavor to provide the logistics and facilities to ensure a smooth take-off and sustenance of kidney transplantation by the Ghanaian team.

Throwing more light on the preparation, Dr Morton said the hospital had come a long way since 2008 after the first transplant.

He said the initial idea was for the local team to start the transplants after a period of assistance from the Birmingham team, but there had been a lot of ups and downs.

He expressed appreciation to the CEO of the hospital for standing firm and providing all the encouragement and support for the national project to be realized.

He said the team would continue with the usual living donor practice where a living person would agree to donate one of his or her kidneys to a recipient.

Dr Morton was hopeful that with time, the country would come up with an elaborate legal framework to support the cadaveric donations.

Cadaveric donation is where the kidney of a brain-dead person but whose heart continues to beat is harvested and given out to someone who needs a kidney transplant.

He said what the hospital needed was a complete centre, either as part of the Urological Centre or a separate transplant unit, which could be expanded to a tissue transplant centre.

Asked about the availability of the requisite human resource, Dr Morton said, “We have demonstrated that we can do it after the first transplant in 2008.”

He said the team of local personnel had continued to be around and actively taken part in the other transplantations and said the only new development was his training as a transplant surgeon.

Dr Morton was hopeful that with time, a complete centre like the National Cardio-Thoracic Centre, the Burns and Plastic Surgery Centre would be set up.

For her part, Dr Osafo, who is the Head of the Dialysis Unit of Korle-Bu, said the local renal team had built the needed experience to support kidney transplant locally.

She said besides the transplant, some of the nephrologists at the unit were considering developing a peritoneal dialysis programme, a form of self-administered dialysis, to help ease the pressure on the dialysis machines.

She expressed worry over the alarming rate at which people in their productive ages of between 20 and 50 years were developing kidney problems in Ghana.

Dr Osafo said the University of Ghana Medical School, in collaboration with other centres in Africa and the USA, had applied for a grant from the National Institute of Health (NIH) to study the genetic causes of kidney disease in Africa.

The outcome of that important application, she said, should be known later this year.

If successful, then patients with kidney disease would be studied at the Korle-Bu Teaching Hospital.**

...

 
China's 3SBio Inc. Announces Unaudited Q1 2012 Results - China Economic Review

3SBio Inc. (NASDAQ: SSRX), a China-based biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products, announced its unaudited financial results for the first quarter ended March 31, 2012.

3SBio is a fully integrated, profitable biotechnology company focused on researching, developing, manufacturing and marketing biopharmaceutical products primarily in China. Its focus is on addressing large markets with significant unmet medical needs in nephrology, oncology, supportive cancer care, inflammation and infectious diseases. With headquarters and GMP-certified manufacturing facilities in Shenyang, PRC, 3SBio employs over 800 people. Shares trade in the form of American Depositary Shares (ADSs) on the NASDAQ stock market under the ticker symbol "SSRX".

First Quarter 2012 Financial Highlights:

- Total net revenues increased by 24.5% over the first quarter of 2011 to RMB147.2 million (US$23.4 million), compared to RMB118.2 million (US$18.1 million) in the first quarter of 2011.

- Operating income was RMB35.5 million (US$5.6 million), compared to operating income of RMB25.3 million (US$3.9 million) in the first quarter of 2011.

- Net income was RMB32.6 million (US$5.2 million), compared to net income of RMB22.2 million (US$3.4 million) in the first quarter of 2011.

- Net income per American Depositary Share ("ADS") on a fully-diluted basis was RMB1.44 (US$0.23) compared to net income per ADS on a fully-diluted basis of RMB0.99 (US$0.15) for the first quarter of 2011.

- Cash, cash equivalents, restricted cash and time deposits were RMB790.8 million (US$125.6 million), including restricted cash of RMB0.7 million.

First Quarter 2012 Business Highlights:

- EPIAO, the Company's flagship injectable recombinant human erythropoietin (EPO) product, demonstrated strong growth with net revenue in the first quarter of 2012 rising 21.7% to RMB83.7 million (US$13.3 million), compared to RMB68.8 million (US$10.5 million) in the first quarter of 2011.

- Net revenues for TPIAO, the Company's novel recombinant human thrombopoietin (TPO) product, increased by 23.3% to RMB46.5 million (US$7.4 million) in the first quarter of 2012, compared to RMB37.7 million (US$5.8 million) in the first quarter of 2011.

- Net revenues for Iron Sucrose Supplement increased by 40.6% to RMB6.8 million (US$1.1 million) in the first quarter of 2012, compared to RMB4.9 million (US$0.7 million) in the first quarter of 2011.

- Net export revenues increased by 80.3% to RMB7.6 million (US$1.2 million), compared to RMB4.2 million (US$0.6 million) in the first quarter of 2011.

...

 
ReCor Medical Completes REDUCE Pilot Clinical Study of Its PARADISE(TM ... - MarketWatch (press release)

MENLO PARK, Calif., May 14, 2012 (BUSINESS WIRE) -- ReCor Medical, an emerging medical device company, announced today that it has completed enrollment in the REDUCE 15-patient pilot clinical study of its PARADISE (Percutaneous Renal Denervation System) ultrasound platform for achieving renal denervation. PARADISE, which is CE-marked, is designed to treat patients with 'resistant' hypertension ("HTN"), a major risk factor for cardiovascular disease.

Current results of the study will be presented from the podium on Thursday, May 17, 08:00-10:20, Room 241, Palais des Congres, by principal investigator Thomas A. Mabin, M.D., Vergelegen Medi-Clinic, South Africa.

Preliminary clinical data for PARADISE were previously reported by Dr. Mabin at the recent "TRenD 2012" transcatheter renal denervation scientific meeting. The PARADISE data showed that systolic blood pressure was reduced by an average of 31 mm Hg in 7 patients at 60-days follow-up. The scientific literature demonstrates that only a 5 mm Hg reduction in BP results in a 14% decrease in stroke, a 9% decrease in heart disease, and a 7% decrease in mortality.

"ReCor's PARADISE system is designed to provide a minimally invasive ultrasound therapy to resistant hypertension patients to help reduce their blood pressure," said Mano Iyer, President & CEO, ReCor Medical. "In the REDUCE study, we have been able to show that our novel PARADISE(TM) system is capable of safely and quickly denervating patients, resulting in sustained blood pressure reductions out to 6 months. We look forward to Dr. Mabin's reporting of the current results of our REDUCE pilot clinical trial at PCR as we move forward with our launch of our PARADISE(TM) system in Europe."

About ReCor Medical, Inc.

Founded in 2009, ReCor is a private venture-backed, early-stage company developing novel therapeutic ultrasound catheter technology. ReCor is backed by European and U.S. investors including Sofinnova Partners, one of the largest life science investors in Europe. The Company's PARADISE(TM) technology for renal denervation is CE-marked. For more information about ReCor Medical, please visit the Company's website at www.recormedical.com .

NOTE: PARADISE(TM) is approved for sale in Europe; it is not approved for sale or investigational use in the United States.

SOURCE: ReCor Medical, Inc.




        
        Media: 
        Ronald Trahan Associates Inc. 
        Ronald Trahan, 1-508-359-4005, x108 
        APR, President
        



Copyright Business Wire 2012

...

 
Dialysis patients finding more local options - Utica Observer Dispatch

A dialysis unit boom has made it easier for patients to get care closer to home at more convenient times.

In the past year, Faxton St. Luke's Healthcare has opened a dialysis unit in Hamilton and expanded its facilities in Rome and at the Masonic Care Community, increasing the total number of stations available from 68 to 96 at its seven locations.

Another eight-station unit will open at St. Luke's Home early next year.

And Bassett Healthcare, which already offered dialysis in Cooperstown and Oneonta, opened a 12-station unit at Little Falls Hospital at the end of 2010.

In Oneida County, 299 patients receive dialysis, and 69 patients receive the treatment in Herkimer County, according to the National Kidney Foundation of Central New York.

Rosa Femia Kahl has benefited from the addition of more units.

Kahl, an Oriskany resident, used to get dialysis three days a week in Oneida, but she switched to Rome in July after that unit expanded. That cut her 1½-hour roundtrip commute to 30 minutes.

“It saves on gas, and I get home earlier,” she said.

The expanded unit also let her change her schedule, so she now gets dialysis first thing in the morning instead of at 11 a.m.

“If I have to go somewhere or make my doctor's appointments, it's a lot easier,” Kahl said.

Diabetes and high blood pressure are the most common causes of chronic kidney disease. When it leads to kidney failure, patients go on dialysis, often for years, while waiting for a transplant.

Patients require dialysis three days a week for about four hours each day. They must follow strict diets that limit fluids, salt, potassium and phosphorous.

Many cope with other serious health problems and numerous medical appointments that must be scheduled around dialysis. Some patients work, but many cannot, while others need someone to drive them to dialysis.

Bassett decided to open the unit after receiving “many, many phone calls of desperate people from the Mohawk Valley, anywhere between Amsterdam and Oneida, lacking chairs,” said Dr. Ann Eldred, senior attending physician of nephrology at Bassett.

People from Herkimer County were driving to Utica, Cooperstown and Syracuse to get treatment, she said.

Some dialysis patients faced even bigger problems in 2008 when the number of people receiving dialysis from Faxton St. Luke's shot up 13 percent, said Kelly Scheinman, executive director of Faxton St. Luke's Regional Dialysis Center. Back then, 54 patients did not have a regular time or place for treatment, she said.

They were fit in at different units at different times whenever an opening popped up, she said. That's when hospital officials began planning the recent expansion, she said.

“We've had a tremendous amount of physical growth in accommodating this increase in numbers that we've seen, basically, since 2008,” Scheinman said.

Although Faxton St. Luke's added a third shift to some dialysis units in 2009 to make sure all patients had consistent appointments, neither the times nor locations were necessarily the most convenient, she said.

But with the recent openings and expansions, patients are able to use the unit closest to their own homes at times that work with their schedules, she said.

And that makes it easier for patients to do what doctors want them to - live lives as similar as possible to their lives before dialysis, Scheinman said.

...

 
Dad cares for son in hospital while mum donates kidney to child - Malaysia Star
Malaysia Star
He is always by the bedside of his son Ong Kok Siong, 26, who suffers from multiple sclerosis and has been warded at the hospital's Institute of Urology and Nephrology for the past year. “For the past three or four years, I have been in and out of the

...

 
<< Start < Prev 381 382 383 384 385 386 387 388 389 390 Next > End >>

Page 388 of 2630
Share |
Copyright © 2024 Global Dialysis. All Rights Reserved.